title: Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.
abstract: The clinical utility of a human epidermal growth factor receptor 2 (HER2)-targeting Affibody molecule for detection and characterization of HER2-positive lesions was investigated in patients with recurrent metastatic breast cancer.
  
  
  METHODS
  Three patients received (111)In- or (68)Ga-labeled DOTA(0)-Z(HER2:342-pep2) (ABY-002). gamma-Camera, SPECT, or PET/CT images were compared with earlier (18)F-FDG PET/CT results.
  
  
  RESULTS
  Administration of radiolabeled ABY-002 was well tolerated. Blood kinetics of radiolabeled ABY-002 showed a first half-life of 4-14 min, second half-life of 1-4 h, and third half-life of 12-18 h. Radiolabeled ABY-002 detected 9 of 11 (18)F-FDG-positive metastases as early as 2-3 h after injection.
  
  
  CONCLUSIONS
  Molecular imaging using (111)In- or (68)Ga-labeled ABY-002 has the potential to localize metastatic lesions in vivo, adds qualitative information not available today by conventional imaging techniques, and may allow the HER2 status to be determined for metastases not amenable to biopsy. To our knowledge, this is the first report on clinical imaging data obtained with a non-immunoglobulin-based scaffold protein.
authors.affiliation: Zentralklinik Bad Berka GmBH, PET-Zentrum, Bad Berka, Germany.
authors.forename: Richard P
authors.initials: RP
authors.lastname: Baum
authors.forename: Vikas
authors.initials: V
authors.lastname: Prasad
authors.forename: Dirk
authors.initials: D
authors.lastname: Müller
authors.forename: Christiane
authors.initials: C
authors.lastname: Schuchardt
authors.forename: Anna
authors.initials: A
authors.lastname: Orlova
authors.forename: Anders
authors.initials: A
authors.lastname: Wennborg
authors.forename: Vladimir
authors.initials: V
authors.lastname: Tolmachev
authors.forename: Joachim
authors.initials: J
authors.lastname: Feldwisch
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D005710:Gallium Radioisotopes / Q000737:chemistry; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007205:Indium Radioisotopes / Q000737:chemistry*; D007267:Injections; D008875:Middle Aged; D057054:Molecular Imaging / Q000379:methods*; D049268:Positron-Emission Tomography; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry* / Q000378:metabolism*; D012008:Recurrence; D014057:Tomography, X-Ray Computed
chemical_list: D005710:Gallium Radioisotopes; D007205:Indium Radioisotopes; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins